JP2024521638A - 好酸球トラップの阻害 - Google Patents

好酸球トラップの阻害 Download PDF

Info

Publication number
JP2024521638A
JP2024521638A JP2023568153A JP2023568153A JP2024521638A JP 2024521638 A JP2024521638 A JP 2024521638A JP 2023568153 A JP2023568153 A JP 2023568153A JP 2023568153 A JP2023568153 A JP 2023568153A JP 2024521638 A JP2024521638 A JP 2024521638A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521638A5 (https=
Inventor
エス、ヘルムス ヘンドリクス ジェラルドゥス ヴァン
ジェラルドゥス シルヴァノ シリヴィ、レナート
モンティザーン、ダフネ
チャールズ メルドラム、エリック
Original Assignee
シトリル ビー．ヴィ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21172160.0A external-priority patent/EP4085973A1/en
Application filed by シトリル ビー．ヴィ． filed Critical シトリル ビー．ヴィ．
Publication of JP2024521638A publication Critical patent/JP2024521638A/ja
Publication of JP2024521638A5 publication Critical patent/JP2024521638A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023568153A 2021-05-04 2022-05-04 好酸球トラップの阻害 Pending JP2024521638A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21172160.0A EP4085973A1 (en) 2021-05-04 2021-05-04 Inhibition of eosinophil extracellular traps
EP21172160.0 2021-05-04
GB2111541.5 2021-08-11
GB202111541 2021-08-11
PCT/EP2022/061970 WO2022233931A1 (en) 2021-05-04 2022-05-04 Inhibition of eosinophilic traps

Publications (2)

Publication Number Publication Date
JP2024521638A true JP2024521638A (ja) 2024-06-04
JP2024521638A5 JP2024521638A5 (https=) 2025-05-15

Family

ID=81392799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568153A Pending JP2024521638A (ja) 2021-05-04 2022-05-04 好酸球トラップの阻害

Country Status (9)

Country Link
US (1) US20250084154A1 (https=)
EP (1) EP4333981A1 (https=)
JP (1) JP2024521638A (https=)
KR (1) KR20240005856A (https=)
AU (1) AU2022270356A1 (https=)
CA (1) CA3215452A1 (https=)
IL (1) IL308223A (https=)
MX (1) MX2023013021A (https=)
WO (1) WO2022233931A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4

Also Published As

Publication number Publication date
IL308223A (en) 2024-01-01
MX2023013021A (es) 2024-02-12
KR20240005856A (ko) 2024-01-12
AU2022270356A1 (en) 2023-09-14
US20250084154A1 (en) 2025-03-13
CA3215452A1 (en) 2022-11-10
WO2022233931A1 (en) 2022-11-10
EP4333981A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
US20220242949A1 (en) Anti-cd166 antibodies and uses thereof
JP7357834B2 (ja) アミロイドベータに対する抗体
RU2732226C2 (ru) Конъюгаты антитело-финомер
CN112930356B (zh) 与瓜氨酸化的组蛋白2a和/或4结合的抗体
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
US20250084154A1 (en) Inhibition of eosinophilic traps
JP6550385B2 (ja) Ｃｃｒ９に対する抗体およびその用途
JP7539834B2 (ja) ガレクチン－３に対する抗体及びその使用方法
TW202400643A (zh) 神經退化性疾病之治療劑
CN120092020A (zh) Cnx抗原结合分子
AU2017207082A1 (en) Anti-Myl9 antibody
CN108431039B (zh) 改进的p2x7受体结合剂和包含其的多肽
JP2023086132A (ja) アミロイドベータに対する抗体
CN112839672A (zh) 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法
CN117396221A (zh) 嗜酸性粒细胞陷阱的抑制
EP4085973A1 (en) Inhibition of eosinophil extracellular traps
EA052640B1 (ru) Ингибирование внеклеточных ловушек
US12161889B2 (en) Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB
CN121219312A (zh) 剂量方案
JP2026513830A (ja) 用量
WO2025120152A1 (en) Diagnostic agent
AU2020216295B2 (en) PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途
US20210324086A1 (en) Anti-galectin-9 antibody and methods of use thereof
HK40126807A (zh) Cnx抗原结合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428